Skip to main content Accessibility help
×
Home
  • Print publication year: 2012
  • Online publication date: April 2013

28 - Minimal residual disease

from Section 3 - Evaluation and treatment

Summary

Introduction

A multitude of clinical and biologic factors have been associated with response to treatment in childhood acute leukemia but their predictive power is far from absolute, and their usefulness for guiding clinical decisions in individual patients is inherently limited. Rather than predicting treatment response, in vivo measurements of leukemia cytoreduction provide direct information on the effectiveness of treatment in each patient. Such estimates, when performed by conventional morphologic techniques, have a relatively low sensitivity and accuracy: in most cases, leukemic cells can be detected in bone marrow with certainty only when they constitute 5% or more of the total cell population. These limitations are overcome by methods for detecting minimal (i.e., submicroscopic) residual disease (MRD), which can be 100 times more sensitive than morphology and allow a more objective assessment of treatment response. The definition of “remission” in patients with acute leukemia by these methods has become the standard at many cancer centers.

Initial reservations about the clinical utility of MRD testing arose from concerns regarding the heterogeneous distribution of leukemia during clinical remission. Another concern was that MRD signals may not correspond to viable leukemic cells with the capacity for renewal. Indeed, even contemporary MRD assays cannot determine whether the signals detected originate from stem cells or from more differentiated cells incapable of driving durable cell growth. In view of the strong correlation between MRD levels and relapse, it is now clear that the presence of MRD in most cases directly or indirectly demonstrates the persistence of leukemic cells that are resistant to chemotherapy and are capable of driving the recurrence of leukemia.

References
Pui, CH, Pei, D, Sandlund, JT, et al. Long-term results of St. Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2010;24:371–382.
Moricke, A, Zimmermann, M, Reiter, A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010;24:265–284.
Kaspers, GJ, Zwaan, CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 2007;92:1519–1532.
Rubnitz, JE. Childhood acute myeloid leukemia. Curr Treat Options Oncol 2008;9:95–105.
Mathe, G, Schwarzenberg, L, Mery, AM, et al. Extensive histological and cytological survey of patients with acute leukaemia in “complete remission.” Br Med J 1966;5488:640–642.
Martens, AC, Schultz, FW, Hagenbeek, A. Nonhomogeneous distribution of leukemia in the bone marrow during minimal residual disease. Blood 1987;70:1073–1078.
Bradstock, KF, Janossy, G, Tidman, N, et al. Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia. Leuk Res 1981;5:301–309.
Bacher, U, Kern, W, Schoch, C, et al. Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia. Cancer 2006;106:839–847.
Saiki, RK, Scharf, S, Faloona, F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985;230:1350–1354.
van der Velden, V, Hochhaus, A, Cazzaniga, G, et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003;17:1013–1034.
Beillard, E, Pallisgaard, N, van der Velden, VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using “real-time” quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): a Europe Against Cancer program. Leukemia 2003;17:2474–2486.
Szczepański, T, Harrison, CJ, van Dongen, JJ. Genetic aberrations in paediatric acute leukaemias and implications for management of patients. Lancet Oncol 2010;11:880–889.
Gabert, J, Beillard, E, van der Velden, V, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe Against Cancer program. Leukemia 2003;17:2318–2357.
Campana, D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009;23:1083–1098, vii.
Bruggemann, M, Schrauder, A, Raff, T, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008. Leukemia 2010;24:521–535.
Mullighan, CG, Collins-Underwood, JR, Phillips, LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009;41:1243–1246.
Yoda, A, Yoda, Y, Chiaretti, S, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2010;107:252–257.
Harvey, RC, Mullighan, CG, Chen, IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010;115:5312–5321.
Cario, G, Zimmermann, M, Romey, R, et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 2010;115:5393–5397.
Boeckx, N, Willemse, MJ, Szczepański, T, et al. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia. Leukemia 2002;16:368–375.
Breit, TM, Beishuizen, A, Ludwig, WD, et al. tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease. Leukemia 1993;7:2004–2011.
Pongers-Willemse, MJ, Seriu, T, Stolz, F, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets. Leukemia 1999;13:110–118.
Carlotti, E, Pettenella, F, Amaru, R, et al. Molecular characterization of a new recombination of the SIL/TAL-1 locus in a child with T-cell acute lymphoblastic leukaemia. Br J Haematol 2002;118:1011–1018.
van Grotel, M, Meijerink, JP, van Wering, ER, et al. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia 2008;22:124–131.
Burmeister, T, Marschalek, R, Schneider, B, et al. Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations. Leukemia 2006;20:451–457.
Meyer, C, Schneider, B, Reichel, M, et al. Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci USA 2005;102:449–454.
van der Velden, V, Corral, L, Valsecchi, MG, et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009;23:1073–1079.
Jansen, MW, Corral, L, van der Velden, V, et al. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia 2007;21:633–641.
Akasaka, T, Muramatsu, M, Ohno, H, et al. Application of long-distance polymerase chain reaction to detection of junctional sequences created by chromosomal translocation in mature B-cell neoplasms. Blood 1996;88:985–994.
zur Stadt, U, Hoser, G, Reiter, A, Welte, K, Sykora, KW. Application of long PCR to detect t(8;14)(q24;q32) translocations in childhood Burkitt's lymphoma and B-ALL. Ann Oncol 1997;8(Suppl 1):31–35.
Wiemels, JL, Cazzaniga, G, Daniotti, M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 1999;354:1499–1503.
Reichel, M, Gillert, E, Breitenlohner, I, et al. Rapid isolation of chromosomal breakpoints from patients with t(4;11) acute lymphoblastic leukemia: implications for basic and clinical research. Leukemia 2001;15:286–288.
Mussolin, L, Basso, K, Pillon, M, et al. Prospective analysis of minimal bone marrow infiltration in pediatric Burkitt's lymphomas by long-distance polymerase chain reaction for t(8;14)(q24;q32). Leukemia 2003;17:585–589.
Lion, T. Current recommendations for positive controls in RT-PCR assays. Leukemia 2001;15:1033–1037.
van der Velden, V, Cazzaniga, G, Schrauder, A, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007;21:604–611.
Yang, L, Han, Y, Suarez, SF, Minden, MD. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007;21:868–876.
Niegemann, E, Wehner, S, Kornhuber, B, Schwabe, D, Ebener, U. WT1 gene expression in childhood leukemias. Acta Haematol 1999;102:72–76.
Bergmann, L, Miething, C, Maurer, U, et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997;90:1217–1225.
Willasch, AM, Gruhn, B, Coliva, T, et al. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. Leukemia 2009;23:1472–1479.
Cilloni, D, Renneville, A, Hermitte, F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009;27:5195–5201.
Jacobsohn, DA, Tse, WT, Chaleff, S, et al. High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival. Br J Haematol 2009;146:669–674.
Tamaki, H, Ogawa, H, Ohyashiki, K, et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999;13:393–399.
Cilloni, D, Gottardi, E, Messa, F, et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 2003;21:1988–1995.
Bader, P, Niemeyer, C, Weber, G, et al. WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia? Eur J Haematol 2004;73:25–28.
Maurer, U, Weidmann, E, Karakas, T, Hoelzer, D, Bergmann, L. Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors. Blood 1997;90:4230–4232.
Doubek, M, Palasek, I, Pospisil, Z, et al. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression. Exp Hematol 2009;37:659–672.
Nakao, M, Janssen, JW, Erz, D, Seriu, T, Bartram, CR. Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: a marker for the monitoring of minimal residual disease. Leukemia 2000;14:522–524.
Meshinchi, S, Stirewalt, DL, Alonzo, TA, et al. Structural and numerical variation of FLT3/ITD in pediatric AML. Blood 2008;111:4930–4933.
Kondo, M, Horibe, K, Takahashi, Y, et al. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Pediatr Oncol 1999;33:525–529.
Kottaridis, PD, Gale, RE, Frew, ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752–1759.
Schnittger, S, Schoch, C, Dugas, M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59–66.
Iwai, T, Yokota, S, Nakao, M, et al. Internal tandem duplication in the juxtatransmembrane domain of the flt3 is not involved in blastic crisis of chronic myeloid leukemia. Leukemia 1997;11:1992–1993.
Kiyoi, H, Naoe, T, Yokota, S, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 1997;11:1447–1452.
Xu, F, Taki, T, Yang, HW, et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br J Haematol 1999;105:155–162.
Meshinchi, S, Woods, WG, Stirewalt, DL, et al. Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001;97:89–94.
Arrigoni, P, Beretta, C, Silvestri, D, et al. FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia. Br J Haematol 2003;120:89–92.
Zwaan, CM, Meshinchi, S, Radich, JP, et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia (AML): prognostic significance and relation to cellular drug resistance. Blood 2003;102:2387–2394.
Rubnitz, JE, Inaba, H, Dahl, GV, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukemia: results of the AML02 multicenter trial. Lancet Oncol 2010;11:543–552.
Ho, PA, Zeng, R, Alonzo, TA, et al. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2010;116:702–710.
Beretta, C, Gaipa, G, Rossi, V, et al. Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia. Leukemia 2004;18:1441–1444.
Schnittger, S, Schoch, C, Kern, W, Hiddemann, W, Haferlach, T. FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia. Acta Haematol 2004;112:68–78.
Kottaridis, PD, Gale, RE, Langabeer, SE, et al. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2002;100:2393–2398.
Shih, LY, Huang, CF, Wu, JH, et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2002;100:2387–2392.
Farr, C, Gill, R, Katz, F, Gibbons, B, Marshall, CJ. Analysis of ras gene mutations in childhood myeloid leukaemia. Br J Haematol 1991;77:323–327.
Cazzaniga, G, Dell'Oro, MG, Mecucci, C, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood 2005;106:1419–1422.
Gorello, P, Cazzaniga, G, Alberti, F, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006;20:1103–1108.
Brown, P, McIntyre, E, Rau, R, et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 2007;110:979–985.
Bernard, OA, Busson-LeConiat, M, Ballerini, P, et al. A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia 2001;15:1495–1504.
Ballerini, P, Blaise, A, Busson-Le Coniat, M, et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood 2002;100:991–997.
Ferrando, AA, Neuberg, DS, Staunton, J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002;1:75–87.
Steinbach, D, Schramm, A, Eggert, A, et al. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin Cancer Res 2006;12:2434–2441.
Greiner, J, Schmitt, M, Li, L, et al. Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood 2006;108:4109–4117.
Tajeddine, N, Millard, I, Gailly, P, Gala, JL. Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia. Clin Chem Lab Med 2006;44:548–555.
Qin, Y, Zhu, H, Jiang, B, et al. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leuk Res 2009;33:384–390.
van Dongen, JJ, Wolvers-Tettero, IL. Analysis of immunoglobulin and T cell receptor genes. Part I: basic and technical aspects. Clin Chim Acta 1991;198:1–91.
Szczepański, T, Orfao, A, van der Velden, VH, San Miguel, JF, van Dongen, JJ. Minimal residual disease in leukaemia patients. Lancet Oncology 2001;2:409–417.
Langerak, AW, Szczepański, T, van der Burg, M, Wolvers-Tettero, IL, van Dongen, JJ. Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations. Leukemia 1997;11:2192–2199.
Delabesse, E, Burtin, ML, Millien, C, et al. Rapid, multifluorescent TCRG Vgamma and Jgamma typing: application to T cell acute lymphoblastic leukemia and to the detection of minor clonal populations. Leukemia 2000;14:1143–1152.
van Dongen, JJ, Wolvers-Tettero, IL. Analysis of immunoglobulin and T cell receptor genes. Part II: possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders. Clin Chim Acta 1991;198:93–174.
Beishuizen, A, Hahlen, K, Hagemeijer, A, et al. Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B-cell origin. Leukemia 1991;5:657–667.
Beishuizen, A, Verhoeven, MA, Mol, EJ, et al. Detection of immunoglobulin heavy-chain gene rearrangements by Southern blot analysis: recommendations for optimal results. Leukemia 1993;7:2045–2053.
van der Burg, M, Barendregt, BH, Szczepański, T, et al. Immunoglobulin light chain gene rearrangements display hierarchy in absence of selection for functionality in precursor-B-ALL. Leukemia 2002;16:1448–1453.
Szczepański, T, Willemse, MJ, van Wering, ER, et al. Precursor-B-ALL with D(H)-J(H) gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia 2001;15:1415–1423.
Siminovitch, KA, Bakhshi, A, Goldman, P, Korsmeyer, SJ. A uniform deleting element mediates the loss of kappa genes in human B cells. Nature 1985;316:260–262.
Seriu, T, Hansen-Hagge, TE, Stark, Y, Bartram, CR. Immunoglobulin kappa gene rearrangements between the kappa deleting element and Jkappa recombination signal sequences in acute lymphoblastic leukemia and normal hematopoiesis. Leukemia 2000;14:671–674.
Felix, CA, Wright, JJ, Poplack, DG, et al. T cell receptor alpha-, beta-, and gamma-genes in T cell and pre-B cell acute lymphoblastic leukemia. J Clin Invest 1987;80:545–556.
Szczepański, T, Beishuizen, A, Pongers-Willemse, MJ, et al. Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease. Leukemia 1999;13:196–205.
van der Velden, V, Bruggemann, M, Hoogeveen, PG, et al. TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse. Leukemia 2004;18:1971–1980.
Bierings, M, Szczepański, T, van Wering, ER, et al. Two consecutive immunophenotypic switches in a child with immunogenotypically stable acute leukaemia. Br J Haematol 2001;113:757–762.
Langerak, AW, Wolvers-Tettero, IL, van den Beemd, MW, et al. Immunophenotypic and immunogenotypic characteristics of TCRgammadelta+ T cell acute lymphoblastic leukemia. Leukemia 1999;13:206–214.
Yokota, S, Hansen-Hagge, TE, Bartram, CR. T-cell receptor delta gene recombination in common acute lymphoblastic leukemia: preferential usage of Vdelta 2 and frequent involvement of the J alpha cluster. Blood 1991;77:141–148.
Steenbergen, EJ, Verhagen, OJ, van Leeuwen, EF, et al. Frequent ongoing T-cell receptor rearrangements in childhood B-precursor acute lymphoblastic leukemia: implications for monitoring minimal residual disease. Blood 1995;86:692–702.
Szczepański, T, van der Velden, VH, Hoogeveen, PG, et al. Vdelta2–Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells. Blood 2004;103:3798–3804.
Szczepański, T, Langerak, AW, Wolvers-Tettero, IL, et al. Immunoglobulin and T cell receptor gene rearrangement patterns in acute lymphoblastic leukemia are less mature in adults than in children: implications for selection of PCR targets for detection of minimal residual disease. Leukemia 1998;12:1081–1088.
Brumpt, C, Delabesse, E, Beldjord, K, et al. The incidence of clonal T-cell receptor rearrangements in B-cell precursor acute lymphoblastic leukemia varies with age and genotype. Blood 2000;96:2254–2261.
van der Velden, V, Szczepański, T, Wijkhuijs, AJ, et al. Age-related patterns of immunoglobulin and T cell receptor gene rearrangements in precursor-B-ALL: implications for detection of minimal residual disease. Leukemia 2003;17:1834–1844.
Peham, M, Panzer, S, Fasching, K, et al. Low frequency of clonotypic Ig and T-cell receptor gene rearrangements in t(4;11) infant acute lymphoblastic leukaemia and its implication for the detection of minimal residual disease. Br J Haematol 2002;117:315–321.
Mann, G, Cazzaniga, G, van der Velden, VH, et al. Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: the ‘big sister' of the infant disease?Leukemia 2007;21:642–646.
Campana, D, van Dongen, JJ, Mehta, A, et al. Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia. Blood 1991;77:1546–1554.
Coustan-Smith, E, Mullighan, CG, Onciu, M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009;10:147–156.
Breit, TM, Wolvers-Tettero, IL, Beishuizen, A, et al. Southern blot patterns, frequencies, and junctional diversity of T-cell receptor-delta gene rearrangements in acute lymphoblastic leukemia. Blood 1993;82:3063–3074.
Langerak, AW, Wolvers-Tettero, IL, van Dongen, JJ. Detection of T cell receptor beta (TCRB) gene rearrangement patterns in T cell malignancies by Southern blot analysis. Leukemia 1999;13:965–974.
Szczepański, T, Langerak, AW, Willemse, MJ, et al. T cell receptor gamma (TCRG) gene rearrangements in T cell acute lymphoblastic leukemia reflect “end-stage” recombinations: implications for minimal residual disease monitoring. Leukemia 2000;14:1208–1214.
Bruggemann, M, van der Velden, V, Raff, T, et al. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia. Leukemia 2004;18:709–719.
van Dongen, JJ, Langerak, AW, Bruggemann, M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene combinations in suspect lymphoproliferations. Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17:2257–2317.
Szczepański, T, Pongers-Willemse, MJ, Langerak, AW, et al. Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. Blood 1999;93:4079–4085.
Adriaansen, HJ, Soeting, PW, Wolvers-Tettero, IL, van Dongen, JJ. Immunoglobulin and T-cell receptor gene rearrangements in acute non-lymphocytic leukemias. Analysis of 54 cases and a review of the literature. Leukemia 1991;5:744–751.
Schmidt, CA, Oettle, H, Neubauer, A, et al. Rearrangements of T-cell receptor delta, gamma and beta genes in acute myeloid leukemia coexpressing T-lymphoid features. Leukemia 1992;6:1263–1267.
Sanchez, I, San Miguel, JF, Corral, J, et al. Gene rearrangement in acute non-lymphoblastic leukaemia: correlation with morphological and immunophenotypic characteristics of blast cells. Br J Haematol 1995;89:104–109.
Kitchingman, GR. Immunoglobulin heavy chain gene VH–D junctional diversity at diagnosis in patients with acute lymphoblastic leukemia. Blood 1993;81:775–782.
Steenbergen, EJ, Verhagen, OJ, van Leeuwen, EF, dem Borne, AE, van der Schoot, CE. Distinct ongoing Ig heavy chain rearrangement processes in childhood B-precursor acute lymphoblastic leukemia. Blood 1993;82:581–589.
Szczepański, T, Willemse, MJ, Kamps, WA, et al. Molecular discrimination between relapsed and secondary acute lymphoblastic leukemia: proposal for an easy strategy. Med Pediatr Oncol 2001;36:352–358.
Szczepański, T, Willemse, MJ, Brinkhof, B, et al. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood 2002;99:2315–2323.
Beishuizen, A, Verhoeven, MA, van Wering, ER, et al. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood 1994;83:2238–2247.
Steward, CG, Goulden, NJ, Katz, F, et al. A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. Blood 1994;83:1355–1362.
Taylor, JJ, Rowe, D, Kylefjord, H, et al. Characterisation of non-concordance in the T-cell receptor gamma chain genes at presentation and clinical relapse in acute lymphoblastic leukemia. Leukemia 1994;8:60–66.
van der Velden, V, Willemse, MJ, van der Schoot, CE, et al. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia 2002;16:928–936.
van Dongen, JJ, Seriu, T, Panzer-Grumayer, ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998;352:1731–1738.
Szczepański, T, van der Velden, VH, Raff, T. Comparative analysis of T-cell receptor gene rearrangements at diagnosis and relapse of T-cell acute lymphoblastic leukemia (T-ALL) shows high stability of clonal markers for monitoring of minimal residual disease and reveals the occurrence of secondary T-ALL. Leukemia 2003;17:2149–2156.
Flohr, T, Schrauder, A, Cazzaniga, G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008;22:771–782.
Knechtli, CJC, Goulden, NJ, Hancock, JP, et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998;92:4072–4079.
Verhagen, OJ, Willemse, MJ, Breunis, WB, et al. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 2000;14:1426–1435.
van der Velden, VH, Wijkhuijs, JM, Jacobs, DC, van Wering, ER, van Dongen, JJ. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia 2002;16:1372–1380.
Langerak, AW, Wolvers-Tettero, IL, Gastel-Mol, EJ, Oud, ME, van Dongen, JJ. Basic helix-loop-helix proteins E2A and HEB induce immature T-cell receptor rearrangements in nonlymphoid cells. Blood 2001;98:2456–2465.
van Wering, ER, van der Linden-Schrever, BE, van der Velden, V, Szczepański, T, van Dongen, JJ. T-lymphocytes in bone marrow samples of children with acute lymphoblastic leukemia during and after chemotherapy might hamper PCR-based minimal residual disease studies. Leukemia 2001;15:1301–1303.
Cazzaniga, G, Biondi, A. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica 2005;90:382–390.
van Dongen, JJ, Breit, TM, Adriaansen, HJ, Beishuizen, A, Hooijkaas, H. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia 1992;6(Suppl 1): 47–59.
Campana, D, Coustan-Smith, E, Janossy, G. The immunologic detection of minimal residual disease in acute leukemia. Blood 1990;76:163–171.
Coustan-Smith, E, Behm, FG, Sanchez, J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998;351:550–554.
Farahat, N, Morilla, A, Owusu-Ankomah, K, et al. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry. Br J Haematol 1998;101:158–164.
Coustan-Smith, E, Sancho, J, Hancock, ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96:2691–2696.
San Miguel, JF, Vidriales, MB, Lopez-Berges, C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001;98:1746–1751.
Dworzak, MN, Froschl, G, Printz, D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002;99:1952–1958.
Coustan-Smith, E, Sancho, J, Behm, FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002;100:52–58.
Coustan-Smith, E, Sancho, J, Hancock, ML, et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002;100:2399–2402.
Borowitz, MJ, Devidas, M, Hunger, SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors a Children's Oncology Group study. Blood 2008;111:5477–5485.
Pui, CH, Campana, D, Pei, D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009;360:2730–2741.
Sutton, R, Venn, NC, Tolisano, J, et al. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. Br J Haematol 2009;146:292–299.
Basso, G, Veltroni, M, Valsecchi, MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009;27:5168–5174.
Wells, DA, Sale, GE, Shulman, HM, et al. Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation. Am J Clin Pathol 1998;110:84–94.
Sievers, EL, Lange, BJ, Alonzo, TA, et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 acute myeloid leukemia patients. Blood 2003;101:3398–3406.
Sang, BC, Shi, L, Dias, P, et al. Monoclonal antibodies specific to the acute lymphoblastic leukemia t(1;19)-associated E2A/pbx1 chimeric protein: characterization and diagnostic utility. Blood 1997;89:2909–2914.
Paolucci, P, Hayward, AR, Rapson, NT. Pre-B and B cells in children on leukaemia remission maintenance treatment. Clin Exp Immunol 1979;37:259–266.
Longacre, TA, Foucar, K, Crago, S, et al. Hematogones: a multiparameter analysis of bone marrow precursor cells. Blood 1989;73:543–552.
Caldwell, CW, Poje, E, Helikson, MA. B-cell precursors in normal pediatric bone marrow. Am J Clin Pathol 1991;95:816–823.
Lucio, P, Parreira, A, van den Beemd, MW, et al. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia 1999;13:419–427.
Ciudad, J, San Miguel, JF, Lopez-Berges, MC, et al. Detection of abnormalities in B-cell differentiation pattern is a useful tool to predict relapse in precursor-B-ALL. Br J Haematol 1999;104:695–705.
van Lochem, EG, Wiegers, YM, van den Beemd, R, et al. Regeneration pattern of precursor-B-cells in bone marrow of acute lymphoblastic leukemia patients depends on the type of preceding chemotherapy. Leukemia 2000;14:688–695.
McKenna, RW, Washington, LT, Aquino, DB, Picker, LJ, Kroft, SH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 2001;98:2498–2507.
Porwit-MacDonald, A, Bjorklund, E, Lucio, P, et al. BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia 2000;14:816–825.
Ciudad, J, San Miguel, JF, Lopez-Berges, MC, et al. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 1998;16:3774–3781.
Lucio, P, Gaipa, G, van Lochem, EG, et al. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation. Leukemia 2001;15:1185–1192.
Weir, EG, Cowan, K, LeBeau, P, Borowitz, MJ. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia 1999;13:558–567.
Dworzak, MN, Fritsch, G, Fleischer, C, et al. Comparative phenotype mapping of normal vs malignant pediatric B-lymphopoiesis unveils leukemia-associated aberrations. Exp Hematol 1998;26:305–313.
Muzzafar, T, Medeiros, LJ, Wang, SA, et al. Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry. Am J Clin Pathol 2009;132:692–698.
Dworzak, MN, Gaipa, G, Ratei, R, et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible. Cytometry B Clin Cytom 2008;74:331–340.
Rhein, P, Mitlohner, R, Basso, G, et al. CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia. Blood 2010;115:3763–3771.
Campana, D, Thompson, JS, Amlot, P, Brown, S, Janossy, G. The cytoplasmic expression of CD3 antigens in normal and malignant cells of the T lymphoid lineage. J Immunol 1987;138:648–655.
Dworzak, MN, Froschl, G, Printz, D, et al. CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. Leukemia 2004;18:703–708.
Coustan-Smith, E, Ribeiro, RC, Stow, P, et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood 2006;108:97–102.
Hurwitz, CA, Loken, MR, Graham, ML, et al. Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. Blood 1988;72:299–307.
Wells, DA, Hall, MC, Shulman, HM, Loken, MR. Occult B cell malignancies can be detected by three-color flow cytometry in patients with cytopenias. Leukemia 1998;12:2015–2023.
Chen, JS, Coustan-Smith, E, Suzuki, T, et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 2001;97:2115–2120.
Veltroni, M, De Zen, L, Sanzari, MC, et al. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia. Haematologica 2003;88:1245–1252.
Gaipa, G, Basso, G, Maglia, O, et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia 2005;19:49–56.
Coustan-Smith, E, Song, G, Clark, C, et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2011;117:6267–6276.
Terstappen, LW, Loken, MR. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. Anal Cell Pathol 1990;2:229–240.
Campana, D, Coustan-Smith, E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999;38:139–152.
Venditti, A, Buccisano, F, Del Poeta, G, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia [In Process Citation]. Blood 2000;96:3948–3952.
Gross, HJ, Verwer, B, Houck, D, Recktenwald, D. Detection of rare cells at a frequency of one per million by flow cytometry. Cytometry 1993;14:519–526.
Stow, P, Key, L, Chen, X, et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010;115:4657–4663.
Neale, GA, Coustan-Smith, E, Pan, Q, et al. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 1999;13:1221–1226.
Inaba, H, Rubnitz, JE, Coustan-Smith, E, et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol 2011;29:3293–3293.
Pui, CH, Raimondi, SC, Behm, FG, et al. Shifts in blast cell phenotype and karyotype at relapse of childhood lymphoblastic leukemia. Blood 1986;68:1306–1310.
Abshire, TC, Buchanan, GR, Jackson, JF, et al. Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia at diagnosis and relapse: a Pediatric Oncology Group study. Leukemia 1992;6:357–362.
Macedo, A, San Miguel, JF, Vidriales, MB, et al. Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease. J Clin Pathol 1996;49:15–18.
van Wering, ER, Beishuizen, A, Roeffen, ET, et al. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. Leukemia 1995;9:1523–1533.
Chucrallah, AE, Stass, SA, Huh, YO, Albitar, M, Kantarjian, HM. Adult acute lymphoblastic leukemia at relapse. Cytogenetic, immunophenotypic, and molecular changes. Cancer 1995;76:985–991.
Guglielmi, C, Cordone, I, Boecklin, F, et al. Immunophenotype of adult and childhood acute lymphoblastic leukemia: changes at first relapse and clinico-prognostic implications. Leukemia 1997;11:1501–1507.
Oelschlagel, U, Nowak, R, Schaub, A, et al. Shift of aberrant antigen expression at relapse or at treatment failure in acute leukemia. Cytometry 2000;42:247–253.
Baer, MR, Stewart, CC, Dodge, RK, et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 2001;97:3574–3580.
Tomova, A, Babusikova, O. Shifts in expression of immunological cell markers in relapsed acute leukemia. Neoplasma 2001;48:164–168.
Dworzak, MN, Schumich, A, Printz, D, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood 2008;112:3982–3988.
Dworzak, MN, Gaipa, G, Schumich, A, et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group. Cytometry B Clin Cytom 2010;78:147–153.
Coustan-Smith, E, Ribeiro, RC, Rubnitz, JE, et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukemia. Br J Haematol 2003;123:243–252.
Cazzaniga, G, Rossi, V, Biondi, A. Monitoring minimal residual disease using chromosomal translocations in childhood ALL. Best Pract Res Clin Haematol 2002;15:21–35.
Radich, JP. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001;15:21–36.
Arico, M, Valsecchi, MG, Camitta, B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342:998–1006.
Kebriaei, P, Larson, RA. Progress and challenges in the therapy of adult acute lymphoblastic leukemia. Curr Opin Hematol 2003;10:284–289.
Gokbuget, N, Kneba, M, Raff, T, et al. Risk-adapted treatment according to minimal residual disease in adult ALL. Best Pract Res Clin Haematol 2002;15:639–652.
Cazzaniga, G, Lanciotti, M, Rossi, V, et al. Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response. Br J Haematol 2002;119:445–453.
Scheuring, UJ, Pfeifer, H, Wassmann, B, et al. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). Blood 2003;101:85–90.
Wassmann, B, Pfeifer, H, Stadler, M, et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2005;106:458–463.
Pane, F, Cimino, G, Izzo, B, et al. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia 2005;19:628–635.
Yanada, M, Sugiura, I, Takeuchi, J, et al. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol 2008;143:503–510.
Biondi, A, Rambaldi, A, Rossi, V, et al. Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation. Blood 1993;82:2943–2947.
Cimino, G, Elia, L, Rivolta, A, et al. Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/AF-4 positive-acute lymphoblastic leukaemia. Br J Haematol 1996;92:659–664.
Ida, K, Taki, T, Bessho, F, et al. Detection of chimeric mRNAs by reverse transcriptase-polymerase chain reaction for diagnosis and monitoring of acute leukemias with 11q23 abnormalities. Med Pediatr Oncol 1997;28:325–332.
Cimino, G, Elia, L, Rapanotti, MC, et al. A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia. Blood 2000;95:96–101.
Cayuela, JM, Baruchel, A, Orange, C, et al. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia. Blood 1996;88:302–308.
Nakao, M, Yokota, S, Horiike, S, et al. Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia. Leukemia 1996;10:1463–1470.
Satake, N, Kobayashi, H, Tsunematsu, Y, et al. Minimal residual disease with TEL-AML1 fusion transcript in childhood acute lymphoblastic leukaemia with t(12;21). Br J Haematol 1997;97:607–611.
Madzo, J, Zuna, J, Muzikova, K, et al. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study. Cancer 2003;97:105–113.
Seyfarth, J, Madsen, HO, Nyvold, C, et al. Post-induction residual disease in translocation t(12;21)-positive childhood ALL. Med Pediatr Oncol 2003;40:82–87.
Metzler, M, Mann, G, Monschein, U, et al. Minimal residual disease analysis in children with t(12;21)-positive acute lymphoblastic leukemia: comparison of Ig/TCR rearrangements and the genomic fusion gene. Haematologica 2006;91:683–686.
Riehm, H, Reiter, A, Schrappe, M, et al. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Padiatr 1987;199:151–160.
Cave, H, van der Werff, tenBosch, J, Suciu, S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer–Childhood Leukemia Cooperative Group. N Engl J Med 1998;339:591–598.
Jacquy, C, Delepaut, B, Van Daele, S, et al. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse. Br J Haematol 1997;98:140–146.
Brisco, MJ, Condon, J, Hughes, E, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994;343:196–200.
Wasserman, R, Galili, N, Ito, Y, et al. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol 1992;10:1879–1888.
Gruhn, B, Hongeng, S, Yi, H, et al. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia 1998;12:675–681.
Goulden, NJ, Knechtli, CJ, Garland, RJ, et al. Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia. Br J Haematol 1998;100:235–244.
Zhou, J, Goldwasser, MA, Li, A, et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood 2007;110:1607–1611.
Conter, V, Bartram, CR, Valsecchi, MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010;115:3206–3214.
Nyvold, C, Madsen, HO, Ryder, LP, et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002;99:1253–1258.
Schrappe, M, Valsecchi, MG, Bartram, CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 200 study. Blood 2011;118:2077–2084.
Scrideli, CA, Assumpcao, JG, Ganazza, MA, et al. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups. Haematologica 2009;94:781–789.
Attarbaschi, A, Mann, G, Panzer-Grumayer, R, et al. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin–Frankfurt–Münster (ALL-BFM) trials. J Clin Oncol 2008;26:3046–3050.
Panzer-Grumayer, ER, Schneider, M, Panzer, S, Fasching, K, Gadner, H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 2000;95:790–794.
Dibenedetto, SP, LoNigro, L, Mayer, SP, Rovera, G, Schiliro, G. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia. Blood 1997;90:1226–1232.
Nizet, Y, Van Daele, S, Lewalle, P, et al. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction. Blood 1993;82:1618–1625.
Neale, GA, Menarguez, J, Kitchingman, GR, et al. Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse. Blood 1991;78:739–747.
Yokota, S, Hansen-Hagge, TE, Ludwig, WD, et al. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 1991;77:331–339.
Biondi, A, Yokota, S, Hansen-Hagge, TE, et al. Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse. Leukemia 1992;6:282–288.
Steenbergen, EJ, Verhagen, OJ, van Leeuwen, EF, et al. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. Leukemia 1995;9:1726–1734.
Eckert, C, Biondi, A, Seeger, K, et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 2001;358:1239–1241.
Paganin, M, Zecca, M, Fabbri, G, et al. Minimal residual disease is an important predictive factor of outcome in children with relapsed “high-risk” acute lymphoblastic leukemia. Leukemia 2008;22:2193–2200.
van der Velden, V, Joosten, SA, Willemse, MJ, et al. Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia 2001;15:1485–1487.
Bader, P, Hancock, J, Kreyenberg, H, et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 2002;16:1668–1672.
Uzunel, M, Mattsson, J, Jaksch, M, Remberger, M, Ringden, O. The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood 2001;98:1982–1984.
Bader, P, Kreyenberg, H, Henze, GH, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009;27:377–384.
Knechtli, CJ, Goulden, NJ, Hancock, JP, et al. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. Br J Haematol 1998;102:860–871.
Ishikawa, K, Seriu, T, Watanabe, A, et al. Detection of neoplastic clone in the hypoplastic and recovery phases preceding acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor delta chain gene. J Pediatr Hematol Oncol 1995;17:270–275.
Morley, AA, Brisco, MJ, Rice, M, et al. Leukaemia presenting as marrow hypoplasia: molecular detection of the leukaemic clone at the time of initial presentation. Br J Haematol 1997;98:940–944.
Goulden, N, Langlands, K, Steward, C, et al. PCR assessment of bone marrow status in ‘isolated' extramedullary relapse of childhood B-precursor acute lymphoblastic leukaemia. Br J Haematol 1994;87:282–285.
Neale, GA, Pui, CH, Mahmoud, HH, et al. Molecular evidence for minimal residual bone marrow disease in children with “isolated” extra-medullary relapse of T-cell acute lymphoblastic leukemia. Leukemia 1994;8:768–775.
O'Reilly, J, Meyer, B, Baker, D, et al. Correlation of bone marrow minimal residual disease and apparent isolated extramedullary relapse in childhood acute lymphoblastic leukaemia. Leukemia 1995;9:624–627.
Hagedorn, N, Acquaviva, C, Fronkova, E, et al. Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of “isolated” and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group. Blood 2007;110:4022–4029.
Cave, H, Guidal, C, Rohrlich, P, et al. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. Blood 1994;83:1892–1902.
Lal, A, Kwan, E, al Mahr, M, et al. Molecular detection of acute lymphoblastic leukaemia in boys with testicular relapse. Mol Pathol 1998;51:277–281.
Vervoordeldonk, SF, Merle, PA, Behrendt, H, et al. PCR-positivity in harvested bone marrow predicts relapse after transplantation with autologous purged bone marrow in children in second remission of precursor B-cell acute leukaemia. Br J Haematol 1997;96:395–402.
Balduzzi, A, Gaipa, G, Bonanomi, S, et al. Purified autologous grafting in childhood acute lymphoblastic leukemia in second remission: evidence for long-term clinical and molecular remissions. Leukemia 2001;15:50–56.
van der Velden, V, Willemse, MJ, Mulder, MF, et al. Clearance of maternal leukaemic cells in a neonate. Br J Haematol 2001;114:104–106.
Greaves, M. In utero origins of childhood leukaemia. Early Hum Dev 2005;81:123–129.
Wiemels, JL, Ford, AM, van Wering, ER, Postma, A, Greaves, M. Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero. Blood 1999;94:1057–1062.
Greaves, M. Molecular genetics, natural history and the demise of childhood leukaemia. Eur J Cancer 1999;35:1941–1953.
Wiemels, J, Kang, M, Greaves, M. Backtracking of leukemic clones to birth. Methods Mol Biol 2009;538:7–27.
Campana, D. Determination of minimal residual disease in leukemia patients. Br J Haematol 2003;121:823–838.
Neale, GA, Coustan-Smith, E, Stow, P, et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 2004;18:934–938.
Kerst, G, Kreyenberg, H, Roth, C, et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol 2005;128:774–782.
Irving, J, Jesson, J, Virgo, P, et al. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting. Haematologica 2009;94:870–874.
van der Velden, V, Jacobs, DC, Wijkhuijs, AJ, et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia 2002;16:1432–1436.
Coustan-Smith, E, Gajjar, A, Hijiha, N, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia 2004;18:499–504.
Raetz, EA, Borowitz, MJ, Devidas, M, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children's Oncology Group Study [corrected]. J Clin Oncol 2008;26:3971–3978.
Mistry, AR, Pedersen, EW, Solomon, E, Grimwade, D. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev 2003;17:71–97.
Lo-Coco, F, Ammatuna, E. Front line clinical trials and minimal residual disease monitoring in acute promyelocytic leukemia. Curr Top Microbiol Immunol 2007;313:145–156.
Wang, ZY, Chen, Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505–2515.
Sanz, MA, Grimwade, D, Tallman, MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113:1875–1891.
Diverio, D, Rossi, V, Avvisati, G, et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter “AIDA” trial. GIMEMA-AIEOP Multicenter “AIDA” Trial. Blood 1998;92:784–789.
Lo-Coco, F, Diverio, D, Avvisati, G, et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999;94:2225–2229.
Burnett, AK, Grimwade, D, Solomon, E, Wheatley, K, Goldstone, AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood 1999;93:4131–4143.
Schnittger, S, Weisser, M, Schoch, C, et al. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003;102:2746–2755.
Gallagher, RE, Yeap, BY, Bi, W, et al. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003;101:2521–2528.
Nucifora, G, Larson, RA, Rowley, JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993;82:712–715.
Kusec, R, Laczika, K, Knobl, P, et al. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 1994;8:735–739.
Saunders, MJ, Tobal, K, Yin, JA. Detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukaemia type M2 after chemotherapy or bone marrow transplantation. Leuk Res 1994;18:891–895.
Jurlander, J, Caligiuri, MA, Ruutu, T, et al. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 1996;88:2183–2191.
Kwong, YL, Chan, V, Wong, KF, Chan, TK. Use of the polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21). Cancer 1995;75:821–825.
Satake, N, Maseki, N, Kozu, T, et al. Disappearance of AML1-MTG8(ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long-term remission. Br J Haematol 1995;91:892–898.
Sugimoto, T, Das, H, Imoto, S, et al. Quantitation of minimal residual disease in t(8;21)-positive acute myelogenous leukemia patients using real-time quantitative RT-PCR. Am J Hematol 2000;64:101–106.
Marcucci, G, Livak, KJ, Bi, W, et al. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia 1998;12:1482–1489.
Barragan, E, Bolufer, P, Moreno, I, et al. Quantitative detection of AML1-ETO rearrangement by real-time RT-PCR using fluorescently labeled probes. Leuk Lymphoma 2001;42:747–756.
Viehmann, S, Teigler-Schlegel, A, Bruch, J, et al. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement. Leukemia 2003;17:1130–1136.
Leroy, H, , BS, Grardel-Duflos, N, et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia 2005;19:367–372.
Perea, G, Lasa, A, Aventin, A, et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia 2006;20:87–94.
Marcucci, G, Caligiuri, MA, Dohner, H, et al. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with inv(16) acute myeloid leukemia. Leukemia 2001;15:1072–1080.
Buonamici, S, Ottaviani, E, Testoni, N, et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002;99:443–449.
van der Reijden, BA, Simons, A, Luiten, E, et al. Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion. Br J Haematol 2002;118:411–418.
Maurillo, L, Buccisano, F, Del Principe, MI, et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008;26:4944–4951.
Lacombe, F, Arnoulet, C, Maynadie, M, et al. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study. Leukemia 2009;23:350–357.